DOC250117C20000
- 0.65
- +0.13+25.00%
Healthpeak Properties Newsroom
Jefferies Maintains Healthpeak Properties(DOC.US) With Buy Rating, Cuts Target Price to $23
Morgan Stanley Maintains Healthpeak Properties(DOC.US) With Hold Rating, Maintains Target Price $23.5
Morgan Stanley Maintains Healthpeak Properties(DOC.US) With Hold Rating, Maintains Target Price $23.5
Analysts Conflicted on These Real Estate Names: Starwood Property (STWD) and Healthpeak Properties (DOC)
Raymond James Initiates Healthpeak Properties(DOC.US) With Hold Rating
Raymond James Keeps Their Hold Rating on Healthpeak Properties (DOC)
Healthpeak Properties Analyst Ratings
Wells Fargo Maintains Equal-Weight on Healthpeak Properties, Lowers Price Target to $22
Wells Fargo Maintains Healthpeak Properties(DOC.US) With Hold Rating, Cuts Target Price to $22
Mizuho Securities Maintains Healthpeak Properties(DOC.US) With Buy Rating, Announces Target Price $24
Mizuho Maintains Outperform on Healthpeak Properties, Lowers Price Target to $24
Healthpeak Properties Analyst Ratings
Citigroup Adjusts Price Target on Healthpeak Properties to $23 From $22, Maintains Neutral Rating
Mizuho Securities Maintains Healthpeak Properties(DOC.US) With Buy Rating
Strategic Growth and Valuation Justify Buy Rating for Healthpeak Properties
Healthpeak Properties Is Maintained at Outperform by RBC Capital
Healthpeak Properties Analyst Ratings
Analysts Offer Insights on Real Estate Companies: VICI Properties (VICI) and Healthpeak Properties (DOC)
RBC Raises Price Target on Healthpeak Properties to $26 From $25
Baird Maintains Healthpeak Properties(DOC.US) With Buy Rating, Raises Target Price to $25